Dietary Supplements for Reduction of Intestinal Permeability Levels

Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · Dec 29, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a dietary supplement on reducing intestinal permeability, also known as "leaky gut syndrome." This condition is linked to having high levels of a protein called zonulin in the stool, which can lead to issues with how well your intestines function. The trial aims to find out if taking this supplement can help lower zonulin levels in people who have been identified with elevated amounts.

To participate in the trial, individuals must be between 18 and 65 years old and have high levels of zonulin (greater than 80 ng/ml) in their stool. However, there are some important exclusions: people who have taken antibiotics, prebiotics, or probiotics in the last month, or those with certain medical conditions or undergoing treatments that could affect their gut health, cannot join. The trial is currently not recruiting participants yet, but once it starts, those eligible can expect to take the supplement and undergo assessments to see how it affects their intestinal permeability.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects between 18 and 65 years of age with elevated levels of zonulin in stool (greater than 80 ng/ml).
• Exclusion Criteria:
• • Taking any type of antibiotic in the last month
• • Taking prebiotics or probiotics products in the last month.
• • Taking laxatives in the last month.
• • Undergoing any medicinal treatment
• • Pregnancy
• • Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.